|Bid||115.52 x 100|
|Ask||136.00 x 100|
|Day's Range||133.02 - 135.43|
|52 Week Range||75.52 - 153.15|
|PE Ratio (TTM)||-238.40|
|Earnings Date||Aug 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||148.64|
Which is the better growth stock going forward -- Exelixis or Incyte? It depends.
Incyte Corporation today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease .
Despite rampant rumors, Gilead is not likely to acquire either Incyte or Vertex. Here's why.